

## DAFTAR PUSTAKA

- Akiyama M, Matsuda Y, Arai T, Saeki H. (2020). PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. *Oncol Lett.* <http://doi.org/10.3892/ol.2020.11325>
- Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017). PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. In *Frontiers in Pharmacology*. Frontiers Media S.A. <https://doi.org/10.3389/fphar.2017.00561>
- Antohe, M., Nedelcu, R. I., Nichita, L., Popp, C. G., Cioplea, M., Brinzea, A., Hodoroagea, A., Calinescu, A., Balaban, M., Ion, D. A., Diaconu, C., Bleotu, C., Pirici, D., Zurac, S. A., & Turcu, G. (2019). Tumor infiltrating lymphocytes: The regulator of melanoma evolution (Review). *Oncology Letters*, 17(5), 4155–4161. <https://doi.org/10.3892/ol.2019.9940>
- Chang, C. Y., Park, H., Malone, D. C., Wang, C. Y., Wilson, D. L., Yeh, Y. M., Van Boemmel-Wegmann, S., & Lo-Ciganic, W. H. (2020). Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients with Advanced Melanoma: A Systematic Review and Network Meta-analysis. *JAMA Network Open*, 3(3). <https://doi.org/10.1001/jamanetworkopen.2020.1611>
- Darmon-Novello, M., Institut, J. A., Roussy, G., Lamant, L., Battistella, M., Saint, H., Nicolas, L., Hopital, O., Mondor, H., Balme, B., Chaltiel, L., & Franchet, C. (2021). *Harmonization of PD-L1 Immunohistochemistry and mRNA Expression Scoring in Metastatic Melanoma: A Multicenter Analysis*. <https://doi.org/10.21203/rs.3.rs-951358/v1>
- D'Mello, S. A. N., Finlay, G. J., Baguley, B. C., & Askarian-Amiri, M. E. (2016). Signaling pathways in melanogenesis. In *International Journal of Molecular Sciences*. MDPI AG. <https://doi.org/10.3390/ijms17071144>
- Domingues, B., Lopes, J. M., Soares, P., & Pópulo, H. (2018). Melanoma treatment in review. In *ImmunoTargets and Therapy*. Dove Medical Press Ltd. <https://doi.org/10.2147/ITT.S134842>
- Elder, D. (2017). *WHO Classification of Skin Tumours* (4th ed.).
- Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016). Cancer immunotherapy: The beginning of the end of cancer? In *BMC Medicine*. BioMed Central Ltd. <https://doi.org/10.1186/s12916-016-0623-5>
- Global Cancer Observatory. (2021). *Melanoma of Skin*.
- Guan, M., Zhu, S., & Li, S. (2021). Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy. In *Frontiers in Bioengineering and Biotechnology*. Frontiers Media S.A. <https://doi.org/10.3389/fbioe.2021.661214>
- Kjeldsen, J. W., Lorentzen, C. L., Martinenaite, E., Ellebaek, E., Donia, M., Holmstroem, R. B., Klausen, T. W., Madsen, C. O., Ahmed, S. M., Weis-Banke, S. E., Holmström, M. O., Hendel, H. W., Ehrnrooth, E., Zocca, M. B., Pedersen, A. W., Andersen, M. H., & Svane, I. M. (2021). A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. *Nature Medicine*, 27(12), 2212–2223. <https://doi.org/10.1038/s41591-021-01544-x>



- Kokkat TJ, Patel MS, McGarvey D, LiVolsi VA, Baloch ZW. (2013). Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. *Biopreserv Biobank*. <http://doi.org/10.1089/bio.2012.0052>
- Lamba, N., Ott, P. A., & Iorgulescu, J. B. (2022). Use of First-Line Immune Checkpoint Inhibitors and Association with Overall Survival among Patients with Metastatic Melanoma in the Anti-PD-1 Era. *JAMA Network Open*, 5(8), E2225459. <https://doi.org/10.1001/jamanetworkopen.2022.25459>
- Lindberg, M. (2018). *Normal Histology*.
- Ma Q, Suo H, Zhu L, Qian Y, Sun X, Xie J, Li Q, Fu Y, Li J, Tao J. Prognostic significance of tumor size for primary invasive cutaneous melanoma: A population-based study, 2004-2016. *Cancer Med*. 2020 Jul;9(13):4561-4571. doi: 10.1002/cam4.3065. Epub 2020 May 5. PMID: 32367684; PMCID: PMC7333855.
- Mahmoud, F., Shields, B., Makhoul, I., Avaritt, N., Wong, H. K., Hutchins, L. F., Shalin, S., & Tackett, A. J. (2017). Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. *Cancer Biology and Therapy*, 18(7), 451–469. <https://doi.org/10.1080/15384047.2017.1323596>
- Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015). The next immune-checkpoint inhibitors: Pd-1/pd-11 blockade in melanoma. In *Clinical Therapeutics*. Excerpta Medica Inc. <https://doi.org/10.1016/j.clinthera.2015.02.018>
- Mauny, M. P. (2017). Ekspresi mRNA Gen PDL-1, PD-1 dan Imunoterapi pada Kanker Kandung Kemih. *Ekspresi MRNA Gen PDL-1, PD-1 Dan Imunoterapi Pada Kanker Kandung Kemih*, 1–30.
- Pachmayr, E., Treese, C., & Stein, U. (2017). Underlying Mechanisms for Distant Metastasis - Molecular Biology. In *Visceral Medicine*. S. Karger AG. <https://doi.org/10.1159/000454696>
- Parker, E. R. (2021). The influence of climate change on skin cancer incidence – A review of the evidence. In *International Journal of Women's Dermatology*. Elsevier Inc. <https://doi.org/10.1016/j.ijwd.2020.07.003>
- Patel, S. P., & Kurzrock, R. (2015). PD-L1 expression as a predictive biomarker in cancer immunotherapy. In *Molecular Cancer Therapeutics*. American Association for Cancer Research Inc. <https://doi.org/10.1158/1535-7163.MCT-14-0983>
- Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., Adriaens, C., Radaelli, E., Wolter, P., Bechter, O., Dummer, R., Levesque, M., Piris, A., Frederick, D. T., Boland, G., ... Marine, J. C. (2018). Toward Minimal Residual Disease-Directed Therapy in Melanoma. *Cell*, 174(4), 843-855.e19. <https://doi.org/10.1016/j.cell.2018.06.025>
- Rauwerdink, D. J. W., van Doorn, R., van der Hage, J., Van den Eertwegh, A. J. M., Haanen, J. B. A. G., Aarts, M., Berkmortel, F., Blank, C. U., Boers-Sonderen, M. J., De Groot, J. W. B., Hospers, G. A. P., de Meza, M., Piersma, D., Van Rijn, R. S., Stevensse, M., Van der Veldt, A., Vreugdenhil, G., Wouters, M. W. J. M., Suijkerbuijk, K., Kapiteijn, E. (2022). Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-



- Riefolo, M., Porcellini, E., Dika, E., Broseghini, E., & Ferracin, M. (2019). Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. In *Molecular Oncology*. John Wiley and Sons Ltd. <https://doi.org/10.1002/1878-0261.12412>
- Rinonce, H. T., Sastri, D. J., Trisnawati, F., Kameswari, B., Ferronika, P., & Irianiwati. (2022). The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia. *Cancer Reports*, 5(1). <https://doi.org/10.1002/cnr2.1454>
- Saputro, R. D., Rinonce, H. T., Iramawasita, Y., Ridho, M. R., Pudjohartono, M. F., Anwar, S. L., Setiaji, K., & Aryandono, T. (2021). Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma. *BMC Research Notes*, 14(1). <https://doi.org/10.1186/s13104-021-05623-7>
- Sorroche, B. P., Teixeira, R. de J., Pereira, C. A. D., Santana, I. V. V., Vujanovic, L., Vazquez, V. de L., & Arantes, L. M. R. B. (2023). PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil. *Diagnostics*, 13(6). <https://doi.org/10.3390/diagnostics13061041>
- Stonesifer, C. J., Djavid, A. R., Grimes, J. M., Khaleel, A. E., Soliman, Y. S., Maisel-Campbell, A., Garcia-Saleem, T. J., Geskin, L. J., & Carvajal, R. D. (2021). Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. In *Frontiers in Oncology*. Frontiers Media S.A. <https://doi.org/10.3389/fonc.2021.734354>
- Sunshine, J. C., Nguyen, P. L., Kaunitz, G. J., Cottrell, T. R., Berry, S., Esandrio, J., Xu, H., Ogurtsova, A., Bleich, K. B., Cornish, T. C., Lipson, E. J., Anders, R. A., & Taube, J. M. (2017). PD-L1 expression in melanoma: A quantitative immunohistochemical antibody comparison. *Clinical Cancer Research*, 23(16), 4938–4944. <https://doi.org/10.1158/1078-0432.CCR-16-1821>
- Tas, F., & Erturk, K. (2020). Primary tumour ulceration in cutaneous melanoma: its role on TNM stages. *Japanese Journal of Clinical Oncology*, 51. <https://doi.org/10.1093/jjco/hyaa191>
- Trinidad, C. M., Torres-Cabala, C. A., Curry, J. L., Prieto, V. G., & Aung, P. P. (2019). Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. *Journal of Clinical Pathology*, 72(4), 265. <https://doi.org/10.1136/jclinpath-2018-205417>
- Vogel, R. I., Strayer, L. G., Ahmed, R. L., Blaes, A., & Lazovich, D. A. (2017). A qualitative study of quality of life concerns following a melanoma diagnosis. *Journal of Skin Cancer*, 2017. <https://doi.org/10.1155/2017/2041872>
- Wang, Y., Gu, T., Tian, X., Li, W., Zhao, R., Yang, W., Gao, Q., Li, T., Shim, J. H., Zhang, C., Liu, K., & Lee, M. H. (2021). A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. *Frontiers in Immunology*, 12. <https://doi.org/10.3389/fimmu.2021.654463>